Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition

Stephen J. Kogut, Diala El-Maouche, Susan M. Abughosh

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Study Objectives. To assess persistence with cholinesterase inhibitor therapy 6 months after the start of treatment, and to determine whether the likelihood of persistence is associated with the coprescription of drugs that can impair cognition. Design. Retrospective cohort study. Setting. Community (home residence) or long-term care facility. Patients. A total of 1183 patients enrolled in the Rhode Island Medicaid program, aged 45 years or older, who were dispensed a cholinesterase inhibitor from January 1, 2000-June 30, 2002. Measurements and Main Results. Patients were considered persistent with treatment if they filled at least five prescriptions for a 1-month supply of the same cholinesterase inhibitor, without an extended gap in days between refills. We compared rates of persistence among patients receiving and those not receiving drugs that can impair cognition. Covariates assessed were patient age, sex, race, and care setting. Approximately one in four patients discontinued cholinesterase inhibitor therapy within 6 months. Patients aged 85 years or older were more persistent than younger patients (77% vs 71%, p<0.05). Caucasian patients were more likely to be persistent than non-Caucasian patients (74% vs 52%, p<0.001). Patients living in the community were less likely to persist than those residing in long-term care facilities (58% vs 76%, p<0.001). After adjusting for race and care setting, patients who were prescribed drugs that can impair cognition were more likely not to have persisted with cholinesterase inhibitor therapy at 6 months than those who did not receive such drugs (odds ratio 1.56, 95% confidence interval 1.13-2.16). Conclusion. A substantial percentage of patients who began receiving cholinesterase inhibitor therapy had discontinued the therapy within 6 months. Many patients also received prescriptions for agents that can impair cognition. Our findings indicated a modest but statistically significant increase in likelihood of treatment discontinuation among patients who also received prescriptions for drugs that can impair cognition. Iatrogenic causes of dementia are important to recognize and address so that therapies for enhancing cognition can be fully effective.

Original languageEnglish (US)
Pages (from-to)1729-1735
Number of pages7
JournalPharmacotherapy
Volume25
Issue number12 I
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Cholinesterase Inhibitors
Cognition
Pharmaceutical Preparations
Therapeutics
Long-Term Care
Prescriptions
Prescription Drugs
Medicaid
Cognitive Therapy
Dementia
Patient Care
Cohort Studies

Keywords

  • Adherence
  • Alzheimer's disease
  • Cholinesterase inhibitors
  • Cognition
  • Dementia
  • Medicaid
  • Persistence

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. / Kogut, Stephen J.; El-Maouche, Diala; Abughosh, Susan M.

In: Pharmacotherapy, Vol. 25, No. 12 I, 12.2005, p. 1729-1735.

Research output: Contribution to journalArticle

Kogut, Stephen J. ; El-Maouche, Diala ; Abughosh, Susan M. / Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. In: Pharmacotherapy. 2005 ; Vol. 25, No. 12 I. pp. 1729-1735.
@article{6c6b4012fffe4869a596da3d068b4a32,
title = "Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition",
abstract = "Study Objectives. To assess persistence with cholinesterase inhibitor therapy 6 months after the start of treatment, and to determine whether the likelihood of persistence is associated with the coprescription of drugs that can impair cognition. Design. Retrospective cohort study. Setting. Community (home residence) or long-term care facility. Patients. A total of 1183 patients enrolled in the Rhode Island Medicaid program, aged 45 years or older, who were dispensed a cholinesterase inhibitor from January 1, 2000-June 30, 2002. Measurements and Main Results. Patients were considered persistent with treatment if they filled at least five prescriptions for a 1-month supply of the same cholinesterase inhibitor, without an extended gap in days between refills. We compared rates of persistence among patients receiving and those not receiving drugs that can impair cognition. Covariates assessed were patient age, sex, race, and care setting. Approximately one in four patients discontinued cholinesterase inhibitor therapy within 6 months. Patients aged 85 years or older were more persistent than younger patients (77{\%} vs 71{\%}, p<0.05). Caucasian patients were more likely to be persistent than non-Caucasian patients (74{\%} vs 52{\%}, p<0.001). Patients living in the community were less likely to persist than those residing in long-term care facilities (58{\%} vs 76{\%}, p<0.001). After adjusting for race and care setting, patients who were prescribed drugs that can impair cognition were more likely not to have persisted with cholinesterase inhibitor therapy at 6 months than those who did not receive such drugs (odds ratio 1.56, 95{\%} confidence interval 1.13-2.16). Conclusion. A substantial percentage of patients who began receiving cholinesterase inhibitor therapy had discontinued the therapy within 6 months. Many patients also received prescriptions for agents that can impair cognition. Our findings indicated a modest but statistically significant increase in likelihood of treatment discontinuation among patients who also received prescriptions for drugs that can impair cognition. Iatrogenic causes of dementia are important to recognize and address so that therapies for enhancing cognition can be fully effective.",
keywords = "Adherence, Alzheimer's disease, Cholinesterase inhibitors, Cognition, Dementia, Medicaid, Persistence",
author = "Kogut, {Stephen J.} and Diala El-Maouche and Abughosh, {Susan M.}",
year = "2005",
month = "12",
doi = "10.1592/phco.2005.25.12.1729",
language = "English (US)",
volume = "25",
pages = "1729--1735",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "12 I",

}

TY - JOUR

T1 - Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition

AU - Kogut, Stephen J.

AU - El-Maouche, Diala

AU - Abughosh, Susan M.

PY - 2005/12

Y1 - 2005/12

N2 - Study Objectives. To assess persistence with cholinesterase inhibitor therapy 6 months after the start of treatment, and to determine whether the likelihood of persistence is associated with the coprescription of drugs that can impair cognition. Design. Retrospective cohort study. Setting. Community (home residence) or long-term care facility. Patients. A total of 1183 patients enrolled in the Rhode Island Medicaid program, aged 45 years or older, who were dispensed a cholinesterase inhibitor from January 1, 2000-June 30, 2002. Measurements and Main Results. Patients were considered persistent with treatment if they filled at least five prescriptions for a 1-month supply of the same cholinesterase inhibitor, without an extended gap in days between refills. We compared rates of persistence among patients receiving and those not receiving drugs that can impair cognition. Covariates assessed were patient age, sex, race, and care setting. Approximately one in four patients discontinued cholinesterase inhibitor therapy within 6 months. Patients aged 85 years or older were more persistent than younger patients (77% vs 71%, p<0.05). Caucasian patients were more likely to be persistent than non-Caucasian patients (74% vs 52%, p<0.001). Patients living in the community were less likely to persist than those residing in long-term care facilities (58% vs 76%, p<0.001). After adjusting for race and care setting, patients who were prescribed drugs that can impair cognition were more likely not to have persisted with cholinesterase inhibitor therapy at 6 months than those who did not receive such drugs (odds ratio 1.56, 95% confidence interval 1.13-2.16). Conclusion. A substantial percentage of patients who began receiving cholinesterase inhibitor therapy had discontinued the therapy within 6 months. Many patients also received prescriptions for agents that can impair cognition. Our findings indicated a modest but statistically significant increase in likelihood of treatment discontinuation among patients who also received prescriptions for drugs that can impair cognition. Iatrogenic causes of dementia are important to recognize and address so that therapies for enhancing cognition can be fully effective.

AB - Study Objectives. To assess persistence with cholinesterase inhibitor therapy 6 months after the start of treatment, and to determine whether the likelihood of persistence is associated with the coprescription of drugs that can impair cognition. Design. Retrospective cohort study. Setting. Community (home residence) or long-term care facility. Patients. A total of 1183 patients enrolled in the Rhode Island Medicaid program, aged 45 years or older, who were dispensed a cholinesterase inhibitor from January 1, 2000-June 30, 2002. Measurements and Main Results. Patients were considered persistent with treatment if they filled at least five prescriptions for a 1-month supply of the same cholinesterase inhibitor, without an extended gap in days between refills. We compared rates of persistence among patients receiving and those not receiving drugs that can impair cognition. Covariates assessed were patient age, sex, race, and care setting. Approximately one in four patients discontinued cholinesterase inhibitor therapy within 6 months. Patients aged 85 years or older were more persistent than younger patients (77% vs 71%, p<0.05). Caucasian patients were more likely to be persistent than non-Caucasian patients (74% vs 52%, p<0.001). Patients living in the community were less likely to persist than those residing in long-term care facilities (58% vs 76%, p<0.001). After adjusting for race and care setting, patients who were prescribed drugs that can impair cognition were more likely not to have persisted with cholinesterase inhibitor therapy at 6 months than those who did not receive such drugs (odds ratio 1.56, 95% confidence interval 1.13-2.16). Conclusion. A substantial percentage of patients who began receiving cholinesterase inhibitor therapy had discontinued the therapy within 6 months. Many patients also received prescriptions for agents that can impair cognition. Our findings indicated a modest but statistically significant increase in likelihood of treatment discontinuation among patients who also received prescriptions for drugs that can impair cognition. Iatrogenic causes of dementia are important to recognize and address so that therapies for enhancing cognition can be fully effective.

KW - Adherence

KW - Alzheimer's disease

KW - Cholinesterase inhibitors

KW - Cognition

KW - Dementia

KW - Medicaid

KW - Persistence

UR - http://www.scopus.com/inward/record.url?scp=29044441116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29044441116&partnerID=8YFLogxK

U2 - 10.1592/phco.2005.25.12.1729

DO - 10.1592/phco.2005.25.12.1729

M3 - Article

C2 - 16305292

AN - SCOPUS:29044441116

VL - 25

SP - 1729

EP - 1735

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 12 I

ER -